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Scedosporium/Pseudallescheria species are frequently seen in cystic ﬁbrosis patients. However, disseminated forms after lung
transplantation in these patients are rarely seen, but often with poor outcome. In this case report we describe a lung
transplant recipient with cystic ﬁbrosis who developed a spondylodiscitis that was caused by Scedosporium apiospermum.T h e
patient was treated with anti-fungal treatment by voriconazole for over three years with a clinical good response and without
the need for surgical intervention. To our opinion this is the ﬁrst anti-fungal treated case of invasive disease caused by
Scedosporium/Pseudallescheria in a cystic ﬁbrosis (CF) patient who underwent lung transplantation that survived.
1.Introduction
Fungi are common and serious causes of infections in lung
transplant recipients and an incidence of these infections
has been reported in 10% to 30%, with a mortality of
up to 60% [1]. The most frequently isolated ﬁlamentous
fungi (moulds) in cystic ﬁbrosis patients are Aspergillus
spp., followed by Scedosporium/Pseudallescheria infections.
Invasive infections with Scedosporium/Pseudallescheria in
CF-patients after lung transplantation are infrequent, but in
the current medical literature, invariably fatal [1–3]. Here,
we report the ﬁrst successfully treated case of invasive disease
with Scedosporium/Pseudallescheria i nac y s t i cﬁ b r o s i s( C F )
patient who underwent lung transplantation.
2.Case
In December 2003, a then 16-year-old female CF patient
underwent bilateral lung transplantation. Her CF disease
(mutation DF508/1717-1GA) was complicated by exocrine
pancreas insuﬃciency, diabetes mellitus, and decreased
growth. Over the years her respiratory tract had been colo-
nized by Staphylococcus aureus and Pseudomonas aeruginosa,
and she suﬀered from recurrent pulmonary infections with
progressive pulmonary dysfunction. Her airways were also
colonized by Scedosporium apiospermum. In December 2003,
she was admitted to the hospital with progression of her
chronic respiratory insuﬃciency, partly due to a severe
pulmonary infection with P. Aeruginosa. Due to her rapid
deterioration she wasadmitted tothe highurgentwaiting list
for lung transplantation. While awaiting a lung transplant
procedure, she received intravenous antibiotic therapy with
ceftazidime and tobramycin, and non-invasive ventilation.
In December 2003 she was successfully transplanted, and
antibiotics were continued up to 2 weeks after the procedure.
Immunosuppressive therapy was instituted with tacrolimus
and mycophenolate, and high ﬁrst doses of prednisone were
tapered to a low maintenance dose of 10mg. Prophylactic2 Case Reports in Infectious Diseases
antiviral therapy (valgancyclovir) was given with cytomegalo
virus (CMV) positive donor and recipient. Because of the
prior colonization with Scedosporium apiospermum prophy-
lactic antifungal therapy was started upon transplantation
with voriconazole, which was continued for 6 months
accordingtoourhospitalprotocolthatisguidedbyearlierlit-
eratureandtaking themediantime ofonsetof4monthsinto
account [2, 4]. Post-transplant her sputum cultures never
showed Scedosporium apiospermum. Prophylactic antifungal
therapy initial regimen after the lung transplantation should
be speciﬁed. Posttransplant her sputum cultures never
showed Scedosporium apiospermum. Some more details on
postoperative immunosuppressive, antiviral, and antifungal
dosage regime would be useful.
Eight months posttransplantation, in August of 2004, the
patient began experiencing lumbar pain without radiation of
the pain or fever. On physical examination, there was no ten-
derness during palpation of lumbar vertebra. Orthopaedic
consultancy diagnosed overextension and prescribed phys-
iotherapy and pain medication. Bone scintigraphy showed
lumbar microfractures. However, in the following months
her lumbar pain did not diminish and therefore a MRI was
performed, which demonstrated a spondylodiscitis at the
levels L2-L3. She was conservatively treated with a corset
and physiotherapy that improved her lumbar pain. In the
following 2 years, periodic lumbar X-rays were performed,
which did not show increased disruption, and sclerosis was
formed. Her lumbar pain disappeared. However, in July
2006, the lumbar pain returned especially during her work
and at night. A MRI of the lumbar region was repeated,
which showed again a spondylodiscitis. This was interpreted
as an active infection of an old focus of spondylodiscitis at
L2-L3, with extension of the infection from L1 to L4 (see
Figure 1) and abscess formation in the left psoas musculus.
A CT-guided ﬁne-needle aspiration of the vertebral lesion
showed a negative culture. Therefore, a surgical biopsy was
performed. Culture of biopsy was positive for Scedosporium
apiospermum, proving the fungal aetiology of the infection.
Susceptibility testing of the isolate yielded the following
minimal inhibitory concentrations (MICs): 0.5mg/L for
voriconazole,2 . 0m g / Lf o rcaspofungin,0 . 5m g / Lf o ritracona-
zol, and 0.25mg/L for posaconazol.
Antifungal therapy was initiated with voriconazole
200mg twice daily, and the lumbar vertebrae were temporar-
ily immobilised with a corset. The lumbar pain diminished,
and after a few weeks, daily activities could slowly be
expanded with careful physiotherapy training. A control
MRI in July 2007 still showed a spondylodiscitis with
disruption of the disci, but the abscess had disappeared.
In January 2008 she was treated with solumedrol for the
suggestion of an acute rejection and in addition, OKT-
3 ,am o n o c l o n a lCD3 antibody (muromonab-CD3), was
administered. One month later a CMV reactivation occurred
for which valgancyclovir was given.
A follow-up MRI (Figure 1) that was performed in
December 2009 showed disappearance of active signs of
spondylodiscitis. Signs of a destructed disk were the only
remaining abnormalities seen on MRI. There were no
signs of toxic side eﬀects (liver transaminases were only
slightly elevated) after prolonged voriconazole therapy in
this patient, and she tolerated it very well. It was decided
to discontinue her treatment with voriconazole after three
and a half years of antifungal therapy. Unfortunately, this
year, she again experienced some lumbar pain and a very
recent MRI showed signs of a relapse at lumbar level 1 twelve
months after discontinuation. We again started voriconazole
treatment. The eﬀect of this treatment has to be evaluated
yet.
3. Discussion
Scedosporium apiospermum is a ﬁlamentous mold present in
soil, sewage, and polluted waters [2, 5]. Up to quite recently,
it was considered the anamorph (asexual stage) of the mould
Pseudallescheria boydii, but recent taxonomical studies have
revealed that in fact, two diﬀerent but very closely related
species exist [6]. S. apiospermum can be distinguished from
the anamorph of P. boydii through its inability to assimilate
D-ribose and the fact that it does not have a sexual stage. The
infections caused by the two species are, however, similar, as
are their susceptibility patterns and current treatments.
Prior to transplantation, Scedosporium/Pseudallescheria
are isolated from upper or lower airway tract material in
6%–10% of CF patients [3]. Due to the colonization of the
sinuses and airways by Scedosporium, CF patients are prone
for development of an invasive fungal disease after lung
transplantation in their concomitant immunosuppressive
status [7].
Six cases of invasive Scedosporium/Pseudoallescheria
infection in posttransplant CF patients have been described
previously [3, 7, 8]. Five cases developed between two and
eight weeks after the transplant procedure, one case after
seven months. All patients had disseminated disease and/or
central nervous system involvement, and, ultimately, none
survived the infection. In four patients, colonization was
demonstrated prior to the transplant procedure.
The patient presented in this report is noteworthy,
as she had an unusual localization of the infection and
because she is the ﬁrst CF patient reported to survive
such an infection. Whether this Scedosporium Apiospermum
infection occurred primarily or secondarily is impossible
to determine. When evaluating the onset of infection after
lung transplantation, a median time of approximately 4
months has been described, but longer periods have been
reported of up to 18 months posttransplantation [2, 4, 8].
However, the long interval between the original complaints
and the diagnosis of spondylodiscitis makes it more likely
that the disk is secondarily infected. It may be possible that
this Scedosporium infection developed by haematogenous
spread from the colonized sinuses, since sputum cultures
did not yield Scedosporium after transplant [1]. Possibly,
dissemination to other organs did not occur, because she did
not require high levels of immunosuppression (i.e., the use
of high dose corticosteroids) for acute rejection.
Voriconazole is generally the antifungal agent of choice
for the treatment of Scedosporium apiospermum [1, 7, 8].
However, the interaction of voriconazole with calcineurin
inhibitors and the elevation of liver enzymes makes adequateCase Reports in Infectious Diseases 3
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Figure 1: (a) and (b) demonstrates the acute spondylodiscitis with destruction of the intervertebral disk between vertebra lumbar 2 and
3 (arrows). (a) (T1 weighted sagittal MRI scan) demonstrates the edema in the adjacent vertebrae as low signal (arrowheads) and (b) (T1
weightedgadolinium-enhancedsagittalMRIscan)showstheenhancementofthevertebraeashighsignal(arrowheads).Imagingﬁndingsare
consistent with spondylodiscitis with psoas muscle abscess (not shown). After therapy, the bone marrow oedema ((c), T1 weighted sagittal
MRI scan) disappeared as did the pathological gadolinium enhancement ((d), T1 weighted gadolinium-enhanced sagittal MRI scan) and
the psoas abscess. The destructed disk (arrows) is the only remaining abnormality, consistent with healed spondylodiscitis.
dosingintherapeuticlevelsratherintricateinlungtransplant
recipients [4], and CF patients may have increased liver
metabolismandhighervoriconazoleclearance[9].Voricona-
zole blood levels should, therefore, be controlled during
treatment [4]. This was not routinely performed in the
past at our department, and we are currently performing
voriconazole bloodlevels on a more regular basis in every
patient.However,theeﬀectofmonitoringvoriconazoleblood
levels in lungtransplant recipients on safety issues has still to
be evaluated in our clinic.
Other cases suggested that the combination of antibiotic
treatment with surgical intervention would give optimal
eradication of the infection focus as a good treatment choice
in both organ transplant recipients and immunocompetent
patients [10–15]. In a recent retrospective analysis of a large
number of fungal central nervous system infections (18% s.
apiospermum),voriconazoleshowedagoodeﬃcacy.Further-
more,prior antifungaltherapy to neurosurgerymay improve
survival [15]. Thus far, we only found one case in the lit-
erature that reported successful treatment with voriconazole
of Scedosporium Proliﬁcans without radical surgery in a
renal transplant recipient with septic arthritis and probable
osteomyelitis [16]. In our case, prolonged voriconazole
therapy without surgery resulted in clinical recovery of the
spondylodiscitis with an excellent improvement on the MRI
(see Figure 1). Nevertheless, our patient showed a relapse
12 months after discontinuation of voriconazole. Therefore,
we suggest that when the S. apiospermum infection has
become manifest, the antifungal treatment period must be
signiﬁcantly expanded and for some patients to even lifelong
therapy [7]. This approach is in agreement with Musk et al.,
who found that prolonged therapy with voriconazole may
improve survival and probably by controlling this fungal
disease [5].
Evidence on the matter remains scarce, but in light of
the aggressive course of Scedosporium and Pseudallescheria
infections, it seems prudent to treat all transplant patients
colonized with these fungi prophylactically with a min-
imum of four-to-six months of antifungal therapy and
possibly longer when a patient receives high dosages of4 Case Reports in Infectious Diseases
immunosuppressive agents [4]. Even then, not every case
will be prevented, and these microorganisms should always
be considered in the diﬀerential diagnosis of posttransplant
infections.
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